Suchergebnisse - "QALYs"

PubPharm (1.627)

61

The value of a QALY towards the end of life and its determinants : Experimental evidence

enthalten in: Social science & medicine (1982) | 2023

von Fischer, B. | Telser, H. | Zweifel, P. | +3

ErratumIn: Soc Sci Med. 2023 Sep;332:116092. - PMID 37506484

62

Enabling QALY estimation in mental health trials and care settings: mapping from the PHQ-9 and GAD-7 to the ReQoL-UI or EQ-5D-5L using mixture models

enthalten in: Quality of life research | 2023

von Franklin, M. | Hernández Alava, M.

63

The trade-off between COVID-19 and mental diseases burden during a lockdown : Mathematical modeling of control measures

enthalten in: Infectious Disease Modelling | 2023

von Romanyukha, A. | Novikov, K. | Avilov, K. | +2

64

Quality of life burden on United States infants and caregivers due to lower respiratory tract infection and adjusting for selective testing : Pilot prospective observational study

enthalten in: Health science reports | 2023

von Hariharan, D. | Kumar, V. | Glaser, E. | +7

65

Assessing micro- vs macro-costing approaches for treating appendicitis in children with appendicectomy or non-operatively

enthalten in: Quality of life research | 2023

von Chorozoglou, M. | Reading, I. | Eaton, S. | +6

66

Reducing the basic reproduction number of COVID-19 : a model simulation focused on QALYs, hospitalisation, productivity costs and optimal (soft) lockdown

enthalten in: The European journal of health economics : HEPAC : health economics in prevention and care | 2023

von Robles-Zurita, J.

67

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

enthalten in: Cost effectiveness and resource allocation : C/E | 2023

von Ong, J. | Than, H. | Tripathi, S. | +2

68

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

enthalten in: Cost effectiveness and resource allocation | 2023

von Ong, J. | Than, H. | Tripathi, S. | +2

69

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

enthalten in: Cost effectiveness and resource allocation | 2023

von Ong, J. | Than, H. | Tripathi, S. | +2

70

Assessing Outcomes for Cost-Utility Analysis in Children and Adolescents With Mental Health Problems : Are Multiattribute Utility Instruments Fit for Purpose?

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2023

von Mihalopoulos, C. | Chen, G. | Scott, J. | +9